Sihuan begins U.S. pirotinib trial

Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:0460) said its Shandong XuanZhu Pharma Co. Ltd. subsidiary began a U.S. Phase I trial of pirotinib ( KBP5209) to treat advanced solid tumors including non-small cell lung, gastric and colorectal cancers.

Sihuan said it worked with Covance Inc. to prepare and begin the trial, which the parties will conduct at the University of Texas MD Anderson Cancer Center, the Indiana University Melvin and Bren Simon Cancer Center and the Huntsman Cancer Institute of the University of Utah. Shandong XuanZhu partnered last week with Covance, the contract research subsidiary of Laboratory Corp. of America Holdings (NYSE:LH), to develop Sihuan's pipeline candidates (see BioCentury Extra, April 6, 2015). ...